• Educational resources
  • Events
  • Expert Panel
No matches
  • Cookie policy
  • Privacy policy
  • About us
  • Join ADVENT

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v4.0 – P Expiration Date: 10/16/2027

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region
Dermatology

World Atopic Eczema Day 2024 | 14 September

In recognition of World Atopic Eczema Day 2024, ADVENT is providing medical education resources to increase the awareness of atopic dermatitis (AD).
Coverpage
Past event
14September2024

Learning objectives

  • Recognize the challenges associated with identifying AD and the consequences of delayed diagnosis on disease progression
  • Utilize various tools to comprehensively monitor disease status and impact of chronic type 2 inflammation in patients with AD
  • Recognize the importance of long-term monitoring and management to positively impact patient burden in AD
Tags
multidisciplinary carequality of life
MAT-GLB-2405706 - 1.0 - 09/2024 and MAT-US-2409144 v1.0 - P Exp Date: 09/13/2026